Medexus Pharmaceuticals Inc (MDP.TO) has seen notable price movements this week, reflecting its ongoing performance and recent announcements.
Medexus Pharmaceuticals Inc, a player in the health care sector, has experienced a solid week in stock performance. As of today, the stock is up 0.98% for the day and 3.85% for the week, which is a positive sign for investors.
Investor takeaway: Investors should pay attention to the company's recent fiscal results and strategic initiatives, as these could impact future performance despite the lack of major news this week.
Advertisement
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeAdvertisement
Market cap
$160.20M
52W high
$5.25
52W low
$2.47
1W change
+2.05%
Beta
1.84
Analyst Price Targets
Based on analyst covering MDP
Wall Street analysts forecast MDP stock price to rise 36.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.81
+36.7% Upside
Current Price
C$4.98
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
49.8%
Annualized
90-Day Vol
42.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$5.95
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$5.29 | C$4.45 – C$6.28 |
| 60 trading days | C$5.61 | C$4.40 – C$7.15 |
| 90 trading days | C$5.95 | C$4.42 – C$8.02 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Medexus Pharmaceuticals Inc has a market cap of C$160.8 million.
The stock is currently trading at C$5.15, significantly above its 200-day moving average of C$3.28, indicating a strong upward trend.
Bull case
Medexus reported strong fiscal year 2026 results, particularly highlighting the momentum of GRAFAPEX. This suggests a positive outlook and potential for continued growth.
Bear case
Despite the recent gains, the company's negative profit margin and return on equity may raise concerns about its long-term sustainability.
Recent Price Action
Advertisement
Medexus Pharmaceuticals Inc (MDP.TO) has seen its stock price increase by 0.98% today, bringing its weekly gain to 3.85%. Over the past month, the stock has surged by 27.93%, and year-to-date, it has risen an impressive 66.02%. This upward momentum may be linked to the company’s recent fiscal year results and ongoing developments in its product offerings.
Company News and Developments
While there are no major news announcements this week, Medexus recently reported strong fiscal year 2026 results, emphasizing the robust performance of its product GRAFAPEX (treosulfan) for Injection. The company has also scheduled a conference call to discuss its fourth fiscal quarter and fiscal year results, which may provide further insights into its strategic direction and financial health. Additionally, Medexus entered into a license and supply agreement for UM171 Cell Therapy in Canada, expanding its portfolio.
Technical Picture
Currently, Medexus Pharmaceuticals is trading at C$5.15, significantly above its 50-day moving average of C$4.18 (up 23.2%) and its 200-day moving average of C$3.28 (up 56.9%). The stock has a 52-week range of C$2.47 to C$5.25, indicating it is trading at 96% of its range. The beta of 1.81 suggests higher volatility compared to the broader market. However, the current trading volume of 28,071 shares is only 0.23 times the 20-day average volume of 54,966 shares, which may indicate lower trading activity relative to recent trends.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
